New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 6, 2011, Pages 508-518

  Laurenti, L ^a   de Padua, L ^a   D'Arena, G ^b   Vannata, B ^a   Innocenti, I ^a   Tarnanil, M ^a   Deaglio, S ^c   Sica, S ^a   Efremov, D G ^d   Leone, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

CD20; CD23; CD37; CD40; CD52; Chronic lymphocytic leukemia; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; APOLIZUMAB; DACETUMUMAB; DACETUZUMAB; EPRATUZUMAB; FLUDARABINE; GALIXIMAB; LUCATUMUMAB; LUMILIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; OBINUTUZUMAB; OFATUMUMAB; RITUXIMAB; RO 5072759; TOSITUMOMAB; TRU 016; TRU 106; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL MEDIATED CYTOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; INFECTION; LEUKOPENIA; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PURE RED CELL ANEMIA; RASH; RESPIRATORY FAILURE; TREATMENT DURATION; TUMOR LYSIS SYNDROME; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, CD40; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; GLYCOPROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, IGE;

EID: 79959474980     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711795843374     Document Type: Article

References (116)

1. Eichhorst, B.F.; Busch, R.; Hopfinger, G.; Pasold, R.; Hensel, M.; Steinbrecher, C.; Siehl, S.; Jäger, U.; Bergmann M.; Stilgenbauer, S.; Schweighofer, S.; Wendtner, C.M.; Döhner, H.; Brittinger, G.; Emmerich, B.; Hallek, M. The German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 2006, 107, 885-891.
2. Flinn, I.W.; Neuberg, D.S.; Grever, M.R.; Dewald, G.W.; Bennett J.M.; Paietta, E.M.; Hussein, M.A.; Appelbaum, F.R.; Larson, R.A.; Moore, D.F.; Tallman, M.S. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol., 2007, 25, 793-798.
3. Catovsky, D.; Richards, S., Matutes, E; Oscier, D.; Dyer, M.J.; Bezares, R.F.; Pettitt, A.R.; Hamblin, T.; Milligan, D.W.; Child, J.A.; Hamilton, M.S.; Dearden, C.E.; Smith A.G.; Bosanquet, A.G.; Davis, Z.; Brito-Babapulle, V.; Else, M.; Wade, R.; Hillmen, P. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet, 2007, 370, 230-239.
4. Robak, T.; Blonski, J.Z.; Gora-Tybor, J.; Jamroziak, K.; Dwilewicz-Trojaczek, J.; Tomaszewska, A.; Konopka, L.; Ceglarek, B.; Dmoszynska A.; Kowal, M.; Kloczko, J.; Holowiecka, B.S.; Sulek, K.; Calbecka M.; Zawilska, K.; Kuliczkowski, K.; Skotnicki, A.B.; Warzocha, K.; Kasznicki, M. The Polish Leukemia Group (PALG CLL2). Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood, 2006, 108, 473-479.
5. Robak, T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr. Cancer Drug Targets, 2008, 8, 156-171.
6. Castillo, J.; Winer, E.; Quesenberry, P. Newer monoclonal antibodies for hematological malignancies. Experimental Hematol., 2008, 36, 755-768.
7. Christian, B.A.; Lin, T.S. Antibody Therapy for Chronic Lymphocytic Leukemia. Semin. Hematol., 2008, 45(2), 95-103.
8. Robak, T. Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity. Curr. Med. Chem., 2009,16, 2212-2234.
9. Robak, T.; Jamroziak, K.; Robak, P. Current and Emerging Treatments for Chronic Lymphocytic Leukaemia. Drugs, 2009; 69 (17), 2415-2449.
10. Hallek, M. Therapy of chronic lymphocytic leukaemia. Best Pract. Res. Clin. Haematol., 2010, 23, 85-96.
11. Cheson, B.D. Monoclonal antibody therapy of chronic lymphocytic leukaemia. Best Pract. Res. Clin. Haematol., 2010, 23, 133-143.
12. Tam, C.S.; Keating, M.J. Chemoimmunoterapy of chronic lymphocytic leukemia. Clin Oncol., 2010, 7, 521-532
13. Jaglowski, S.M.; Alinari, L.; Lapalombella, R.; Muthusamy, N.; Byrd, J.C. The clinical application of monoclonal antibodies in chronic lymphocytic leukaemia. Blood, 2010, 116(19), 3705-3714
14. Johnson, P.; Glennie, M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol., 2003, 30(1 Suppl 2), 3-8.
15. Teeling, J.L.; Mackus, W.J.; Wiegman, L.J.; van den Brakel, J.H.; Beers, S.A.; French, R.R.; van Meerten, T.; Ebeling, S.; Vink, T.; Slootstra, J.W.; Parren, P.W.; Glennie, M.J.; van de Winkel, J.G. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol., 2006, 177(1), 362-371.
16. Mossner, E.; Brunker, P.; Moser, S.; Pntener, U.; Schmidt, C.; Herter, S.; Grau R.; Gerdes, C.; Nopora, A.; van Puijenbroek, E.; Ferrara, C.; Sondermann, P.; Jager, C.; Strein, P.; Fertig G.; Friess, T.; Schull, C.; Bauer, S.; Dal Porto, J.; Del Nagro, C.; Dabbagh, K.; Dyer, M.J.S.; Poppema, S.; Klein, C.; Umana P. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood, 2010, 115, 4393-4402.
17. Cartron, G.; Watier, H.; Golay, J.; Solal-Celigny, P. From the bench to the bedside: ways to improve rituximab efficacy. Blood, 2004, 104(9), 2635-2642.
18. Glennie, M.J., French, R.R.; Cragg, M.S.; Taylor, R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol., 2007, 44(16), 3823-3837.
19. Taylor, R.P.; Lindorfer, M.A. Immunotherapeutic Mechanisms of Anti-CD20 Monoclonal Antibodies. Curr. Opin. Immunol., 2008, 20(4), 444-449.
20. Chan, H.T.; Hughes, D.; French, R.R.; Tutt, A.L.; Walshe, C.A.; Teeling, J.L.; Glennie, M.J.; Cragg, M.S. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100-insoluble membrane rafts. Cancer Res., 2003, 63(17), 5480-5489.
21. Cragg, M.S.; Glennie, M.J. Antibody specificity controls in vivo effector mechanisms of anti- CD20 reagents. Blood, 2004, 103 (7), 2738-2743.
22. Hagenbeek, A.; Gadeberg, O.; Johnson, P.; Moller Pedersen, L.; Walewski, J.; Hellmann, A.; Link, B.K.; Robak, T.; Wojtukiewicz, M.; Pfreundschuh, M.; Kneba, M.; Engert, A.; Sonneveld, P.; Flensburg, M.; Petersen, J.; Losic, N.; Radford, J. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 2008, 111(12), 5486-5495.
23. Beers, S.A.; Chan, C.H.; James, S.: French, R.R; Attfield, K.E.; Brennan, C.M; Ahuja, A.; Shlomchik, M.J.; Cragg, M.S.; Glennie, M.G. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood, 2008; 112(10), 4170-4177.
24. Golay, J.; Zaffaroni, L.; Vaccari, T.; Lazzari, M.; Borleri, G.M.; Bernasconi, S. Tedesco, F.; Rambaldi, A.; Introna, M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood, 2000, 95, 3900-3908.
25. Treon, S.P.; Mitsiades, C.; Mitsiades, N.; Young, G.; Doss, D.; Schlossman, R.; Anderson, K.C: Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with Bcell malignancies. J. Immunother., 2001, 24, 263-271.
26. Byrd, J.C.; Kitada, S.; Flinn, I.W.; Aron, J.L.; Pearson, M.D.; Lucas, D.; Reed, J. C. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood, 2002, 99, 1038-1043.
27. Pedersen, I.M.; Buhl, A.M.; Klausen, P.; Geisler, C.H.; Jurlander, J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cellchronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood, 2002, 99, 1314-1319.
28. Maloney, D.G.; Grillo-López, A.J.; Bodkin, D.J.; White, C.A.; Liles, T.M.; Royston, I.; Varns, C.; Rosenberg, J.; Levy, R. IDECC2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol., 1997, 15(10), 3266-74.
29. McLaughlin, P.; Grill-Lopez, A.J.; Link, B.K.; Levy, R.; Czuczman, M.S.; Williams, M.E.; Heyman, M.R.; Bence-Bruckler, I.; White C.A.; Cabanillas, F.; Jain, V.; Ho A.D.; Lister, J.; Wey, K.; Shen, D.; Dallaire, B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four-dose treatment program. J. Clin. Oncol., 1998, 16, 2825-2833.
30. Byrd, J.C.; Waselenko, J.K.; Maneatis, T.J.; Murphy, T.; Ward, F.T.; Monahan, B.P.; Sipe, M.A.; Donegan, S.; White, C.A. Rituximab therapy in hematologic malignancy patients with irculating blood tumor cells: association with increased infusionrelated side effects and rapid blood tumor clearance. J. Clin. Oncol., 1999, 17(3), 791-795.
31. Nguyen, D.T.; Amess, J.A.; Doughty, H.; Hendry, L.; Diamond, L.W. IDECC2B8 anti-CD20 (rituximab) immunotherapy in patients with low grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur. J. Haematol., 1999, 62, 76-82.
32. Hainsworth, J.D.; Litchy, S.; Barton, J.H.; Houston, G.A.; Hermann, R.C.; Bradof, J.E.; Greco, F.A.; Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 2003, 21, 1746-1751.
33. Tam, C.S; Otero-Palacios, J.; Abruzzo, L.V.; Jorgensen, J.L.; Ferrajoli, A.; Wierda, W.G., Lerner, S.; O'Brien, S.; Keating, M.J. Chronic lymphocytic leukaemia CD20 expressionis dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br. J. Hematol., 2008, 141, 36-40.
34. Manshouri, T. Do K.; Wang, X.; Giles, F.J.; O'Brien, S.M.; Saffer, H.; Thomas, D.; Jilani, I.; Kantarjian, H.M; Keating, M.J.; Albitar, M. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukaemia and is of prognostic significance. Blood, 2003, 101, 2507-2513.
35. Byrd, J.C.; Murphy, T.; Howard, R.S.; Lucas, M.S.; Goodrich, A.; Park, K.; Pearson, M.; Waselenko, J.K.; Ling, G.; Grever, M.R.; Grillo-Lopez, A.J.; Rosenberg, J.; Kunkel, L.; Flinn, I.W. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol., 2001, 19 (8), 2153-2164.
36. O'Brien, S.M.; Kantarjian, H.; Thomas, D.A. Giles, F.J.; Freireich, E.J.; Cortes, J.; Lerner, S.; Keating, M.J. Rituximab dose-escalation trial in chronic lymphocytic leukaemia. J. Clin. Oncol. 2001, 19 (8), 2165-2170
37. Schulz, H.; Klein, S.K.; Rehwald, U.; Reiser, M.; Hinke, A.; Knauf, W.U.; Aulitzky, W.E.; Hensel, M.; Herold, M.; Huhn, D.; Hallek, M.; Diehl, V.; Engert, A. German CLL Study Group. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood, 2002, 100(9), 3115-31120.
38. Byrd, J.C.; Peterson, B.L.; Morrison, V.A.; Park, K.; Jacobson, R.; Hoke, E.; Vardiman, J.W.; Rai, K.; Schiffer, C.A.; Larson, R.A.; Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 2003, 101(1), 6-14.
39. Robak, T.; Dmoszynska, A.; Solal-Céligny, P.; Warzocha, K.; Loscertales, J.; Catalano, J.; Afanasiev, B.V.; Larratt, L.; Geisler, C.H.; Montillo, M.; Zyuzgin, I.; Ganly, P.S.; Dartigeas, C.; Rosta, A.; Maurer, J.; Mendila, M.; Saville, M.W.; Valente, N.; Wenger, M.K.; Moiseev, S.I. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol., 2010, 28, 1756-1765.
40. Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink A.M.; Busch, R.; Mayer, J.; Hensel, M.; Hopfinger, G.; Hess, G.; von Grünhagen, U.; Bergmann, M.; Catalano, J.; Zinzani, P.L.; Caligaris-Cappio, F.; Seymour, J.F.; Berrebi, A.; Jäger, U.; Cazin, B.; Trneny, M.; Westermann, A.; Wendtner, C.M.; Eichhorst, B.F.; Staib, P.; Bühler, A.; Winkler, D.; Zenz, T.; Böttcher, S.; Ritgen, M.; Mendila M.; Kneba, M.; Döhner, H.; Stilgenbauer, S. International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 2010, 376 (9747), 1164-1174.
41. Garvey, B. Rituximab in the treatment of autoimmune haematological disorders. Br. J.Hematol., 2008, 141, 149-169.
42. Zecca, M.; De Stefano, P.; Nobili, B.; Locatelli, F. Anti-CD20 monoclonal antibody for the treatment of severe, immunemediated, pure red cell aplasia and hemolytic anemia. Blood, 2001, 97(12), 3995-3997.
43. Hegde, U.P.; Wilson, W.H.; White, T.; Cheson, B.D. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood, 2002, 100(6), 2260-2262.
44. Edwards, JCW, Cambridge, G. B-cell targeting in rheumatoid arthritis and other autoimmune disease. Nat. Rev. Immunol., 2006, 6, 394-403.
45. Dervite, I.; Hober, D.; Morel, P. Acute hepatitis B in a patients with antibodies to hepatitis B surface antigen who was receiving rituximab. N. Engl. J. Med., 2001, 344, 68-69.
46. Carson, K.R.; Focosi, D.; Major, E.O.; Petrini, M.; Richey, E.A.; West, D.P.; Bennett, C.L. Monoclonal antibody-associated progressive multifocal leucoencephalopathy inpatients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol., 2009, 10, 816-824.
47. Robak T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev. Anticancer Ther., 2008, 8, 1033-1051.
48. Demko, S.; Summers, J.; Keegan, P.; Pazdur, R. FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia. The Oncol., 2008, 13, 167-174.
49. Osterborg, A.; Foa, R.; Bezares, R.F.; Dearden, C.; Dyer, M.J.S.; Geisler, C.; Lin, T.S.; Montillo, M.; van Oers, M.H.J.; Wendtner, C.M.; Rai K.R. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukaemia. Leukemia, 2009, 23, 1980-1988.
50. Riechmann, L.; Clark, M.; Waldmann, H.; Winter, G. Reshaping human antibodies for therapy. Nature, 1988, 332, 323-327.
51. Xia, M.Q.; Hale, G.; Waldmann, H. Efficient complementmediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol. Immunol., 1993, 30, 1089-1096.
52. Mone, A.P.; Cheney, C.; Banks, A.L.; Tridandapani, S.; Mehter, N.; Guster S.; Lin, T.; Eisenbeis, C.F.; Young, D.C.; Byrd, J.C. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia, 2006, 20, 272-279.
53. Smolewski, P.; Szmigielska-Kaplon, A.; Cebula, B.; Jamroziak, K.; Rogalinska, M.; Kilianska, Z.; Robak, T. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk. Lymphoma., 2005, 46, 87-100.
54. Stanglmaier, M.; Reis, S.; Hallek, M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in Blymphoid cell lines and in chronic lymphocytic leukemia cells. Ann. Hematol., 2004, 83, 634-645.
55. Zent, C.S.; Chen, J.B.; Kurten, R.C.; Kaushal, G.P.; Lacy, H.M.; Schichman, S.A. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk. Res., 2004, 28, 495-507.
56. Zent, C.S.; Secreto, C.R.; Laplant, B.R.; Bone, N.D.; Call, T.G.; Shanafelt, T.D.; Jelinek, D.F.; Tschumper R.C.; Kay N.E. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res., 2008, 32, 1849-1856.
57. Osterborg, A.; Dyer, M.J.; Bunjes, D.; Pangalis, G.A.; Bastion, Y.; Catovsky, D.; Mellstedt, H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J. Clin. Oncol., 1997, 15(4),1567-1574.
58. Rai, K.R.; Freter, C.E.; Mercier, R.J.; Cooper, M.R.; Mitchell, B.S.; Stadtmauer, E.A.; Santábarbara, P.; Wacker, B.; Brettman, L. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol., 2002, 20(18), 3891-3897.
59. Keating, M.J.; Flinn, I.; Jain, V. Binet, J.L; Hillmen, P.; Byrd, J.; Albitar, M.; Brettman, L.; Santabarbara, P.; Wacker, B.; Rai, K.R. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 2002, 99(10), 3554-35561.
60. Stilgenbauer S.; Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med., 2002, 347(6), 452-453.
61. Lozanski, G.; Heerema, N.A., Flinn, I.W.; Smith, L.; Harbison, J.; Webb, J.; Moran, M.; Lucas, M.; Lin, T.; Hackbarth, M.L.; Proffitt, J.H.; Lucas, D.; Grever, M.R.; Byrd, J.C. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood, 2004, 103(9), 3278-3281.
62. Laurenti, L.; Piccioni, P.; Cattani, P.; Cingolani, A.; Efremov, D.G.; Chiusolo, P.; Tarnani, M.; Fadda, G.; Sica, S.; Leone, G. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica, 2004, 89(10), 1248-1252.
63. Hillmen, P.; Skotnicki, A.B.; Robak, T.; Jaksic, B.; Dmoszynska, A.; Wu, J.; Sirard, C.; Mayer, J. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol., 2007, 25, 5616-5623.
64. Lundin, J.; Kimby, E.; Björkholm, M.; Broliden, P.A.; Celsing, F.; Hjalmar, V.; Möllgård, L.; Rebello, P.; Hale, G.; Waldmann, H.; Mellstedt, H.; Österborg, A. Phase II trial of subcutaneous anti CD- 52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukaemia (B-CLL). Blood, 2002, 100, 768-773.
65. Stilgenbauer, S.; Zenz, T.; Winkler, D.; Bühler, A.; Schlenk, R.F.; Groner, S.; Busch, R.; Hensel, M.; Dührsen, U.; Finke, J.; Dreger, P.; Jäger, U.; Lengfelder, E.; Hohloch, K.; Söling, U.; Schlag, R.; Kneba, M.; Hallek, M.; Döhner, H. German Chronic Lymphocytic Leukemia Study Group. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic ymphocytic Leukemia Study Group. J. Clin. Oncol., 2009, 27(24), 3994-4001.
66. Cortelezzi, A.; Pasquini, M.C.; Cardellini, A.; Granelli, U.; Bossi, A.; Reda, G.; Sarina, B.; Musto, P.; Barcellini, W.; Neri, A.; Deliliers, G.L. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia, 2009, 23, 2027-2033.
67. Laurenti, L.; Piccioni, P.; Tarnani, M.; Efremov, D.G.; Fiorini, A.; Garzia, M.; Sica, S. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience. Haematologica., 2005, 90(8), 1143-1145.
68. Tarnani, M.; D'Arena, G.; Efremov, D.G.; Marietti, S.; Leone, G., Laurenti, L. The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia. Leukemia, 2010, 24(4), 890-891.
69. Lundin, J.; Porwit-MacDonald, A.; Rossmann, E.D.; Karlsson, C.; Edman, P.; Rezvany, M.R.; Kimby, E.; Osterborg, A.; Mellstedt, H. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia, 2004, 18(3), 484-490.
70. Laurenti, L.; Piccioni, P.; Tarnani, M.; Chiusolo P.; Piccirillo, N.; Rumi, C.; Sora, F.; Sica, S.; Leone, G. Immune recovery after lowdose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia. Leukemia., 2005, 19(1), 153-154.
71. Engert, A.; Gercheva, L.; Robak, T.; Galina, P.; Wu, J.; Sirard, C.A.; Elter, T. Improved progression-free survival (PFS) of alemtuzumab (Campath_, Mab-Campath_) plus fludarabine (Fludara_) versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukemia: preliminary results from a phase III randomized trial. Blood., 2009, 114(22), 537a.
72. Elter, T.; James R.; Stilgenbauer, S.; Boettcher, S.; Ritgen, M.; Doehner, H.; Hallek M.; Engert, A. Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group. Blood, 2009, 114, 209a.
73. Coiffier, B.; Lepretre, S.; Pedersen, L.M.; Gadeberg, O.; Fredriksen, H.; van Oers, M.H.J; Wooldridge, J.; Kloczko, J.; Holowiecki, J.; Hellmann, A.; Walewski, J.; Flensburg, M.; Petersen, J.; Robak, T. Safety and efficacy ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. A phase 1-2 study. Blood, 2008; 11, 1094-1100.
74. Robak, T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr. Opin. Mol. Ther., 2008, 10, 294-309.
75. Wierda, W.G.; Kipps, T.J.; Mayer, J. Stilgenbauer, S.; Williams, C.D.; Hellmann, A.; Robak, T.; Furman, R.R; Hillmen, P.; Trneny, M.; Dyer, M.J.S.; Padmanabhan S.; Piotrowska, M.; Kozak, T.; Chan, G.; Davis, R.; Losic, N.; Wilms, J.; Russell, C.A.; Österborg, A. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol., 2010, 28, 1749-55.
76. Sanford, M.; McCormack, P.L. Ofatumumab. Drugs, 2010, 70(8), 1013-1019.
77. Lemery, S.J.; Zhang, J.; Rothmann, M.D.; Yang, J.; Earp, J.; Zhao, H.; McDougal A.; Pilaro, A.; Chiang, R.; Gootenberg, J.E.; Keegan, P.; Pazdur, R. U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab. Clin. Cancer Res., 2010, 16(17), 4331-4338.
78. GlaxoSmithKline; Research Triangle Park (NC). Prescribing information. Arzerra (ofatumumab). October 2009.
79. Beum, P.V.; Lindorfer, M.A.; Beurskens, F.; Stukenberg, P.T.; Lokhorst, H.M.; Pawluczkowycz, A.W.; Parren, P.W.; van de Winkel, J.G.; Taylor, R.P. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol., 2008, 181, 822-832.
80. Teeling, J.L.; French, R.R.; Cragg, M.S.; van den Brakel, J.; Pluyter, M.; Huang, H.; Chan, C.; Parren, P.W.H.I.; Hack, C.E.; Dechant, M.; Valerius, T.; van de Winkel, J.G.J.; Glennie, M.J. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood, 2004, 104, 1793-1800.
81. Pawluczkowycz, A.; Beurskens, F.; Beum, P.V. Lindorfer, M.A., van de Winkel, J.G.; Parren, P.W.; Taylor, R.P. Binding of submaximal C1q promotes complement dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): Considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol., 2009, 183, 749-758.
82. Bleeker, W.K.; Munk, M.E.; Mackus, W.J. van den Brakel, J.H.; Pluyter, M.; Glennie, M.J.; van de Winkel, J.G.; Parren, P.W. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol., 2008, 140(3), 303-312.
83. GlaxoSmithKline. Arzerra: prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125326lbl.pdf [Accessed 2010 Jan 25]
84. Wierda, W.G.; Kipps, T.J.; Durig J.; Griskevicius, L.; Stilgenbauer, S.; Mayer, J.; Smolej, L.; Hess, G.; Griniute, R.; Hernandez-Ilizaliturri, F.J.; Padmanabhan, S.; Gorczyca, M.; Chan, G.; Gupta, I.; Andersen, M.; Strange, C.; Nielsen, T.G.; Russell, C.A. Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial. Blood, 2009, 114(22), 207a.
85. European Medicines Agency. Arzerra: summary of opinion (initial authorisation) [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/opinion/Arzerra_214261en.pdf [Accessed 2010 Jan 25]
86. Umana, P.; Moessner, E.; Bruenker, P.; Gabriele, K.; Ursula, P.; Suter, T.; Grau, R.; Schmidt, C.; Herter, S.; Gerdes, C.; Nopora, A.; Patre, M.; Moser, S.; Sondermann, P.; Wheat, L.; Dyer, M.J.S.; Poppema, S.; Bauer, S.; Kubbies, M.; Strein, P.; Fertig, G.; Friess, T.; Dabbagh, K.; Dal Porto, J.; Klein, C. GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and anhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo. Blood, 2007, 110, 2348a.
87. Salles, G.; Morschhauser, F.; Cartron, G.; Lamy, T.; Milpied, N.J.; Thieblemont, C.; Tilly, H.; Birkett, J.; Burgess, M. Aphase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20_ malignant disease. Blood, 2008, 112, 234a.
88. Robak, T. GA-101, a third-generation, humanized and glycoengineered anti CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr. Opin. Investig. Drugs, 2009, 10, 588-596.
89. Ferrara, C.; Stuart, F.; Sondermann, P.; Brunker, P.; Umana, P.; The carbohydrate at FcgammaRIIIa Asn-162: an element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem., 2006, 281(8), 5032-5036.
90. Niederfellner, G.J.; Lammens, A.; Schwaiger, M.; Georges, G.; Wiechmann, K.; Franke, A.; Schaefer, W.; Jenewein, S.; Slootstra, J.; Moessner, E.; Umana, P.; Hopfner, K.P; Klein, C. Crystal Structure Analysis Reveals That the Novel Type II Anti-CD20 Antibody GA101 Interacts with a Similar Epitope as Rituximab and Ocrelizumab but in a Fundamentally Different Way. Blood, 2009, 114(22), 3726a.
91. Alduaij, W.; Potluri, S.; Ivanov, A.; Honeychurch, J.; Beers, S.A.; Chan C.; Shimada, K.; Glennie, M.J.; Cragg, M.S.; Illidge, T. New- Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma. Blood, 2009, 114(22), 725a.
92. Ivanov, A.; Beers, S.A.; Walshe, C.A.; Honeychurch, J.; Alduaij, W.; Cox, K.L.; Potter, K.N.; Murray, S.; Chan, C.H.; Klymenko, T.; Erenpreisa, J.; Glennie, M.J.; Illidge, T.M.; Cragg, M.S. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J. Clin. Invest., 2009, 19(8), 2143-2159.
93. Zenz, T.; Volden, M.; Mast, T.; Sarno, A.; Winkler, D.; Schnaiter, A.; Bühler, A.; Klein, C.; Umana, P.; Döhner, H.; Stilgenbauer, S. In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL. Blood, 2009, 114(22), 2379a.
94. Patz M.; Forcob N.; Muller B.; Klein C.; Umana P.; Hallek M.; Krause G. Depletion of chronic lymphocytic leukemia cells from whole blood samples mediated by the anti-CD20 antibodies rituximab and GA101. Blood, 2009, 114(22), 2365a.
95. Morschhauser, F.; Cartron, G.; Lamy, T.; Milpied, N.J., Thieblemont, C.; Tilly, H.; Weisser, M.; Birkett, J.; Salles, J.A. Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 2009, 114(22), 884a.
96. Hulkkonen, J.; Vilpo, L.; Hurme, M.; Vilpo, J. Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and effects of chromosomal abnormalities. Leukemia, 2002, 16(2), 178-185.
97. Gong, J.Z.; Lagoo, A.S.; Peters, D.; Horvatinovich, J.; Benz, P.; Buckley, P.J. Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/ small lymphocytic lymphoma. Am. J. Clin. Pathol., 2001, 116(6), 893-897.
98. Pathan, N.I.; Chu, P.; Hariharan, K.; Cheny, C.; Molina, A.; Byrd, J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23_ lymphoma cell lines. Blood, 2008, 111(3),1594-1602.
99. Byrd, JC.; O'Brien, S.; Flinn, IW.; Kipps, TJ.; Weiss, M.; Rai, K.; Lin, TS.; Woodworth, J.; Wynne, D.; Reid, J.; Molina, A.; Leigh, B.; Harris, S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res., 2007, 13(15 pt 1), 4448-4455.
100. Byrd, J.C.; Kipps, T.J.; Flinn, I.W.; Castro, J.; Lin, T.S.; Wierda, W.; Heerema, N.; Woodworth, J; Hughes, S.; Tangri, S.; Harris, S.; Wynne, D.; Molina, A.; Leigh, B.; O'Brien, S. Phase study of lumiliximab combined with fludarabine, cyclophosphamide and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood, 2010, 115, 489-495.
101. Robak, T.; Robak, P.; Smolewski, P. TRU-016, a humanized anti- CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr. Opin. Investig. Drugs, 2009, 10, 1383-90.
102. Andritsos, L.; Furman, R.; Flinn, I.W. A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL. J. Clin. Oncol., 2009, 27(15), 3017a.
103. Zhao, X.; Lapalombella, R.; Joshi, T.; Cheney, C.; Gowda, A.; Hayden-Ledbetter, M.S.; Baum, P.R.; Lin, T.S.; Jarjoura, D.; Lehman, A.; Kussewitt, D.; Lee, R.J, Caligiuri, M.A.; Tridandapani, S.; Muthusamy, N.; Byrd, J.C. Targeting CD37- positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007, 110(7), 2569-2577.
104. Baum, P.R.; Cerveny, C.; Gordon, B.; Nilsson, C.; Wiens, J.; Rafiq, S.; Lapalombella, R.; Muthusamy, N.; Byrd, J.C.; Wahl, A. Evaluation of the effect of TRU-16, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non- Hodgkin's lymphoma. J. Clin. Oncol., 2009, 27(15), 8571a
105. Andritsos, L.; Furman, R.R.; Flinn, I.W.; Foreno-Torres, A.; Flynn, J.M.; Muthusamy, N.; Rafiq, S.; Stromatt, S.; Byrd, J.C. A Phase 1 Trial of TRU-016, An Anti- CD37 Small Modular Immunopharmaceutical (SMIPTM) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity. Blood, 2009, 114(22), 3124a.
106. Furman, R.R.; Forero-Torres, A.; Shustov, A.; Drachman, J.G. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma., 2010, 51(2), 228-235.
107. Hsu, S.J.; Esposito, L.A.; Aukerman, S.L.; Kantak, S.; Mirza, A.M. HCD122 an antagonist human anti-CD40 monoclonal antibody, inhibits tumor growth in xeno-graft models of human diffuse large B-cell lymphoma, a subsets of non-Hodgkin's lymphoma. Blood, 2006, 108 (11), 2519a.
108. Tong, X.; Aukerman, S.L.; Lin, K.; Aziz, N.; Goldbeck, C.; Georgakis, G.V.; Younes, A.; Weng, W.K. O'Brien, S.; Wierda, W.; Jallal, B.; Luqman, M. A non-internalizing anti-CD40 antibody CHIR-0.12.12, blocks CD40 L-induced cytokine production and mediated greater ADCC than rituximab in primary CLL cells. Blood, 2005, 106 (11), 2964a.
109. Byrd, J.C.; Flinn, I.W.; Khan, K.D.; Kipps, T.J.; Aukerman, L.; Fox, J.; Girish, S.; Guzy, S.; Bilic S.; Solinger, A.; Dort, S.; Wang, Y.; Hurst, D.; O'Brien, S. Pharmacokinetics and pharmacodynamics from a first-in-human phase 1 dose escalation study with antagonist anti-CD40 antibody HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 2006, 108 (11), 2837a.
110. Kostelny, S.A.; Link, B.K.; Tso, J.Y.; Vasquez, M.; Jorgensen, B.H.; Wang, H.G.; Hall, W.C.; Weiner, G.J. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int. J. Cancer, 2001, 93, 556-565.
111. Lin, T.S.; Stock, W.; Xu, H.; Phelps, M.A.; Lucas, M.S.; Guster, S.K.; Briggs, B.R.; Cheney, C.; Porcu, P.; Flinn, I.W.; Grever, M.R.; Dalton, J.T.; Byrd, J.C. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk. Lymphoma., 2009, 50(12), 1958-1963.
112. Carnahan, J.; Stein, R.; Qu, Z.; Hess, K.; Cesano, A.; Hansen, H.J.; Goldenberg, D.M. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol. Immunol., 2007, 44(6), 1331-1341.
113. Carnahan, J.; Wang, P.; Kendall, R.; Chen, C.; Hu, S.; Boone, T.; Juan, T.; Talvenheimo, J.; Montestruque, S.; Sun, J.; Elliott, G.; Thomas, J.; Ferbas, J.; Kern, B.; Briddell, R.; Leonard, J.P.; Cesano, A. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin. Cancer Res., 2003, 9 (10), 3982a.
114. Czuczman, M.S.; Thall, A.; Witzig, T.E. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory ollicular lymphoma. J. Clin. Oncol., 2005, 23, 4390-4403
115. Huhn, D.; von Schilling, C.; Wilhelm, M.; Ho, A.D.; Hallek, M.; Kuse, R.; Knauf, W.; Riedel, U.; Hinke, A.; Srock, S.; Serke, S.; Peschel, C.; Emmerich, B. German Chronic Lymphocytic Leukemia Study Group. Rituximab therapy of patients with B-cell hronic lymphocytic leukemia. Blood, 2001, 98(5), 1326-13.
116. Dreger, P.; Corradini, P.; Kimby, E.; Michallet, M.; Milligan, D.; Schetelig, J.; Wiktor-Jedrzejczak, W.; Niederwieser, D.; Hallek, L.; Montserrat, E. Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia, 2007, 21, 12-17.